STRATEGIC NEWS WATCH — July 21, 2026
|
Novo Nordisk’s federal lawsuit against Eli Lilly turned the GLP-1 rivalry into a courtroom fight, headlining a day that also brought an early FDA action date for Dyne’s Duchenne therapy and a Leqvio-powered return to growth at Novartis. Today’s top developments:
|
What to Watch
- Novo v. Lilly injunction — A New Jersey court ruling on Novo’s requested injunction and corrective-advertising demand could reset how comparative GLP-1 claims are marketed direct-to-consumer across the obesity market.
- Dyne FDA decision (January 21, 2027) — With accelerated approval sought and no advisory committee planned, a green light would put z-rostudirsen into direct competition with Sarepta’s Exondys 51 in exon-51 Duchenne.
- Agios pipeline reset — Investors will watch how Agios reallocates capital after dropping tebapivat and whether its narrowed focus makes the company a more attractive M&A target.
- Leqvio cardiovascular outcomes (2027) — Two outcomes readouts due next year will test Novartis’ above-$4 billion peak sales thesis for inclisiran as oral PCSK9 inhibitors enter the market.
- Gross-to-net pressure — Widening list-to-net spreads at eight top manufacturers suggest political pressure on list prices may do little to net revenue unless rebate architecture is reformed alongside it.
This brief highlights the edition’s top stories. Read the full July 21, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.